Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Objective. We sought new susceptibility markers for rheumatoid arthritis (RA) among the T cell receptor y (TCRy) genes.Methods. We analyzed restriction fragment length polymorphisms (RFLP) of the first variable subgroup of TCRy genes in a group of French control subjects and a group of French RA patients.Results. No significant difference in Eco RI HFLP was found between the 2 study populations: Allele frequencies were virtually identical. There was no polymorphism using Hind 111.Conclusion. These results exclude TCRVyI polymorphism as a disease susceptibility marker in RA.Rheumatoid arthritis (RA), a common anti potentially disabling disease, develops in genetically susceptible hosts, as demonstrated by the association with certain HLA class I1 DRP alleles (1). RA results in T lymphocyte infiltration of the synovium, with paradoxical proliferative characteristics (2). IiLA class I1 molecules participate in the immune process by presenting peptides to T lymphocytes, which spe- The variable domains of the chains constituting the TCR a/@ or y/a heterodimers are encoded by V genes, D segments (for P and a), and J segments, which undergo somatic rearrangements, thus generating the combinatorial diversity of the TCR repertoire. Sequential rearrangements seem to begin with the TCRy locus (3), leading either to limited TCRy/S expression on 5% of human circulating T lymphocytes, or to P and then a gene rearrangements, producing a functional d p receptor in most peripheral T cells (4). As a consequence of this chronology, the y genes are rearranged in all dp+ and y/6+ T lymphocytes.Restriction fragment length polymorphisms (RFLP) of the TCRy genes have been previously documented for the constant region genes in various normal populations, showing either a duplication or a triplication of exon 2 of TRGC2, and for the variable region genes belonging to the VyI and to the VyIV subgroups (for review, see ref. 5). Seven haplotypes resulting from a variation of the Vyl subgroup gene number due to deletion, insertion events, or polymorphic restriction sites have been described (5,6).Numerous attempts have been made, with conflicting results (for review, see ref . 7), to analyze the T cell repertoire associated with the development of RA, either by dissecting the TCR-expressing subset distribution or by seeking an oligoclonal T cell response to a hypothetical dominant antigen. However, little is known about the possible influence of ontogenic rearrangements on the TCR repertoire during the pathogenesis of RA. A number of investigators, including
Objective. We sought new susceptibility markers for rheumatoid arthritis (RA) among the T cell receptor y (TCRy) genes.Methods. We analyzed restriction fragment length polymorphisms (RFLP) of the first variable subgroup of TCRy genes in a group of French control subjects and a group of French RA patients.Results. No significant difference in Eco RI HFLP was found between the 2 study populations: Allele frequencies were virtually identical. There was no polymorphism using Hind 111.Conclusion. These results exclude TCRVyI polymorphism as a disease susceptibility marker in RA.Rheumatoid arthritis (RA), a common anti potentially disabling disease, develops in genetically susceptible hosts, as demonstrated by the association with certain HLA class I1 DRP alleles (1). RA results in T lymphocyte infiltration of the synovium, with paradoxical proliferative characteristics (2). IiLA class I1 molecules participate in the immune process by presenting peptides to T lymphocytes, which spe- The variable domains of the chains constituting the TCR a/@ or y/a heterodimers are encoded by V genes, D segments (for P and a), and J segments, which undergo somatic rearrangements, thus generating the combinatorial diversity of the TCR repertoire. Sequential rearrangements seem to begin with the TCRy locus (3), leading either to limited TCRy/S expression on 5% of human circulating T lymphocytes, or to P and then a gene rearrangements, producing a functional d p receptor in most peripheral T cells (4). As a consequence of this chronology, the y genes are rearranged in all dp+ and y/6+ T lymphocytes.Restriction fragment length polymorphisms (RFLP) of the TCRy genes have been previously documented for the constant region genes in various normal populations, showing either a duplication or a triplication of exon 2 of TRGC2, and for the variable region genes belonging to the VyI and to the VyIV subgroups (for review, see ref. 5). Seven haplotypes resulting from a variation of the Vyl subgroup gene number due to deletion, insertion events, or polymorphic restriction sites have been described (5,6).Numerous attempts have been made, with conflicting results (for review, see ref . 7), to analyze the T cell repertoire associated with the development of RA, either by dissecting the TCR-expressing subset distribution or by seeking an oligoclonal T cell response to a hypothetical dominant antigen. However, little is known about the possible influence of ontogenic rearrangements on the TCR repertoire during the pathogenesis of RA. A number of investigators, including
Non-obese diabetic (NOD) mice become spontaneously diabetic as a result of a genetically programmed autoimmune process mediated by autoreactive T lymphocytes and directed against beta cell antigen(s). Studies dealing with T cell receptor (TcR) variable (V) gene usage by such autoreactive T lymphocytes have given contrasted results. Various reasons may explain these discrepancies: the multiplicity of antigenic epitopes putatively recognized by T cells, the ambiguity between specifically committed T cells and passenger lymphocytes homing randomly to the pancreas, the necessarily limited size of the T cell clone panels which have been analyzed for TcR rearrangements and, last but not least, the flexibility of T cell repertoires. To circumvent some of these difficulties, we have decided to concentrate upon the T cell population present in diseased animals and capable of transferring diabetes into young naive NOD recipients. This population, composed of CD4+ and CD8+ T cells, is presumably committed against the relevant beta cell antigens and is the most likely to reveal a bias in V gene usage if such a bias does indeed exist. To find out whether certain V beta genes are more frequently used than others by such pathogenic T cells, T lymphocytes from diabetic donors have been depleted in vitro of defined V beta subsets before being reinoculated into permissive recipients. Out of four V beta families probed under such conditions, three (V beta 8, V beta 5 and V beta 11) are neutral. Their absence neither increases nor reduces the final incidence of successful transfers, indicating that these gene segments are not preferentially used. In contrast, the depletion of V beta 6-positive T cells results in a severe reduction of transfers, suggesting that V beta 6 gene is used with a relatively high frequency by diabetogenic CD4+ and/or CD8+ T cells. To define more precisely which subset uses V beta 6 gene preferentially, we have performed mixing experiments with deleted and intact subsets. The results, based on disease transfer and insulitis severity, indicate that the V beta 6 bias affects predominantly the CD4+ subset. Thus, at variance with several studies concluding that V gene usage in NOD mice is heterogeneous, our present data suggest that disease transferring T cells use a relatively restricted set of V beta genes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.